{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:14:18Z","timestamp":1791476058553,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.clindermatol.2023.08.003","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T01:47:30Z","timestamp":1691977650000},"page":"523-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biologic therapies for psoriasis and eyes"],"prefix":"10.1016","volume":"41","author":[{"given":"Alicja","family":"Burek-Michalska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Turno-Kr\u0119cicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Grzybowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2023.08.003_bib0001","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0002","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0003","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.3390\/ijms20184347","article-title":"Risk factors for the development of psoriasis","volume":"20","author":"Kamiya","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0004","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0005","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/1756-185X.12505","article-title":"Sleep quality in patients with psoriatic arthritis","volume":"20","author":"Gezer","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0006","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/1203475420952420","article-title":"The incidence and prevalence of uveitis in psoriasis: a systematic review and meta-analysis","volume":"24","author":"Lam","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9308341","article-title":"Psoriasis and risk of uveitis: a systematic review and meta-analysis","volume":"2020","author":"Chaiyabutr","year":"2020","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0008","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s10792-022-02225-5","article-title":"Psoriasis and uveitis","volume":"42","author":"K\u00f6se","year":"2022","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.737256","article-title":"Managing psoriatic arthritis with inflammatory bowel disease and\/or uveitis","volume":"8","author":"Chia","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0010","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/rheumatology\/keaa062","article-title":"Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis","volume":"59","author":"Pittam","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21207488","article-title":"New treatment addressing the pathogenesis of psoriasis","volume":"21","author":"Tokuyama","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0012","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102731","article-title":"Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment","volume":"20","author":"Br\u00fcner","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0014","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/ijd.12744","article-title":"Pharmacology and therapeutics recalcitrant psoriatic uveitis and anti-tumor necrosis factor-a monoclonal antibodies: experience from a psoriasis referral center","volume":"54","author":"Fotiadou","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/09273940802023786","article-title":"Biologic response modifier therapy for psoriatic ocular inflammatory disease","volume":"16","author":"Huynh","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0016","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients","volume":"119","author":"D\u00edaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0017","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/bjophthalmol-2011-301401","article-title":"A three-centre experience with adalimumab for the treatment of non-infectious uveitis","volume":"97","author":"Dobner","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0018","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3109\/09273948.2013.779727","article-title":"Long-term clinical outcomes in patients with refractory uveitis associated with Beh\u00e7et disease treated with infliximab","volume":"21","author":"al Rashidi","year":"2013","journal-title":"Ocul Immun Inflamm"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0019","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00417-013-2552-8","article-title":"Anti-TNF-\u03b1 agents for refractory cystoid macular edema associated with noninfectious uveitis","volume":"252","author":"Schaap-Fogler","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0021","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/IAE.0000000000001269","article-title":"Infliximab therapy in patients with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy","volume":"37","author":"Maleki","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0022","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar4582","article-title":"Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study","volume":"16","author":"Kaltsonoudis","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0023","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2006.01.012","article-title":"Adalimumab-associated optic neuritis","volume":"244","author":"Chung","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0024","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/1346-8138.12062","article-title":"Optic neuritis in a psoriatic arthritis patient treated by infliximab","volume":"40","author":"Minami-Hori","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0025","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4161\/mabs.1.5.9286","article-title":"Golimumab","volume":"1","author":"Mazumdar","year":"2009","journal-title":"mAbs"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0026","first-page":"96","article-title":"Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis","author":"G\u00f3mez-G\u00f3mez","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0027","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/jdv.13662","article-title":"Treatment of psoriasis with etanercept: the typical patient profile","volume":"30","author":"Prinz","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0028","first-page":"719","article-title":"Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0029","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaad.2014.08.050","article-title":"OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results","volume":"72","author":"Kimball","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0030","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0031","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn's disease: an integrated analysis of phase II\/III clinical development programs","volume":"42","author":"Ghosh","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0032","first-page":"30","article-title":"Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis","author":"Mugheddu","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0033","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/ijd.14509","article-title":"Are new variants of psoriasis therapy (IL-17 inhibitors) safe?","volume":"58","author":"Wcis\u0142o-Dziadecka","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0034","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520969494","article-title":"Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report","volume":"48","author":"Lu","year":"2020","journal-title":"J Int Med Res"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0035","first-page":"91","article-title":"Psoriasis and uveitis: links and risks","volume":"9","author":"Fotiadou","year":"2019","journal-title":"Psoriasis (Aukl)"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0036","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0037","doi-asserted-by":"crossref","DOI":"10.1186\/s12348-020-00202-6","article-title":"A review of ocular adverse events of biological anti-TNF drugs","volume":"10","author":"Nicolela Susanna","year":"2020","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0038","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/ard.2006.066787","article-title":"Optic neuritis occurring with anti-tumour necrosis factor \u03b1 therapy","volume":"66","author":"Simsek","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2023.08.003_bib0039","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/aos.12515","article-title":"Toxic optic neuropathies: an updated review","volume":"93","author":"Grzybowski","year":"2015","journal-title":"Acta Ophthalmol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X23000822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X23000822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:20:53Z","timestamp":1760034053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X23000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0738081X23000822"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2023.08.003","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic therapies for psoriasis and eyes","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2023.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}